Quality of Life in the Trastuzumab for Gastric Cancer Trial

Satoh, Taroh; Bang, Yung‐Jue; Gotovkin, Evgeny; Hamamoto, Yasuo; Kang, Yoon‐Koo; Moiseyenko, Vladimir; Ohtsu, Atsushi; Cutsem, Éric Van; Al-Sakaff, N.; Urspruch, A.; Hill, Julie; Weber, Heinz; Chung, Haerim

doi:10.1634/theoncologist.2014-0058

Cited by 47 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although some data exist on QoL associated with palliative chemotherapy for advanced gastric cancer6, 7, 8, QoL data associated with surgical palliation are sparse9 10. The aim of this study was to examine the impact of surgical palliation on postoperative QoL in patients with malignant gastric outlet obstruction caused by incurable advanced gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer

Fujitani¹,

Ando

Sakamaki

et al. 2017

BJS Open

View full text Add to dashboard Cite

BackgroundQuality of life (QoL) is a key component in decision‐making for surgical palliation, but QoL data in association with surgical palliation in advanced gastric cancer are scarce. The aim of this multicentre observational study was to examine the impact of surgical palliation on QoL in advanced gastric cancer.MethodsThe study included patients with gastric outlet obstruction caused by incurable advanced primary gastric cancer who had no oral intake or liquid intake only. Patients underwent palliative distal/total gastrectomy or bypass surgery at the physician's discretion. The primary endpoint was change in QoL assessed at baseline, 14 days, 1 month and 3 months following surgical palliation by means of the EuroQoL Five Dimensions (EQ‐5D™) questionnaire and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire gastric cancer module (QLQ‐STO22). Secondary endpoints were postoperative improvement in oral intake and surgical complications.ResultsSome 104 patients (23 distal gastrectomy, 9 total gastrectomy, 70 gastrojejunostomy, 2 exploratory laparotomy) were enrolled from 35 institutions. The mean EQ‐5D™ utility index scores remained consistent, with a baseline score of 0·74 and the change from baseline within ± 0·05. Gastric‐specific symptoms showed statistically significant improvement from baseline. The majority of patients were able to eat solid food 2 weeks after surgery and tolerated it thereafter. The rate of overall morbidity of grade III or more according to the Clavien–Dindo classification was 9·6 per cent (10 patients) and the 30‐day postoperative mortality rate was 1·9 per cent (2 patients).ConclusionIn patients with gastric outlet obstruction caused by advanced gastric cancer, surgical palliation maintained QoL while improving solid food intake, with acceptable morbidity for at least the first 3 months after surgery. Registration number 000023494 (UMIN Clinical Trials Registry).

show abstract

Section: Introductionmentioning

confidence: 99%

Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer

Fujitani¹,

Ando

Sakamaki

et al. 2017

BJS Open

View full text Add to dashboard Cite

show abstract

“…The ToGA trial also provided evidence of a prolongation of time to the deterioration of healthrelated quality of life [14]. Furthermore, the subgroup analyses of the ToGA trial restricted to Japanese patients [15] and a subsequent similar phase III study recruiting only Chinese patients [16] have confirmed again such promising results, suggesting the efficacy of trastuzumab irrespective of country of origin.…”

Section: Gastric Cancermentioning

confidence: 85%

Molecular Targeting Therapy for Gastric Cancer: Current Advances and Obstacles

Shimoyama¹

2017

Gastric Cancer

View full text Add to dashboard Cite

Although the incidence of gastric cancer (GC) has declined steadily in recent years, GC remains a major cancer burden. Multimodal therapies have been developed and first-line chemotherapy for advanced GC patients, even they have good performance status, could provide only modest efficacy. Furthermore, treatment outcomes after failure of first-line chemotherapy remain poor. In order to provide a solution to this unmet clinical need, since the management of various types of cancer has progressed rapidly into the molecular era, biomarker-targeted therapy for GC has received enormous attention in recent years. This review focuses on the current treatment achievement of molecular targeting agents for GC, such as trastuzumab, pertuzumab, trastuzumab emtansine, lapatinib, cetuximab, panitumumab, nimotuzumab, mammalian target of rapamycin, bevacizumab, ramucirumab, sunitinib, sorafenib, apatinib, rilotumumab, and onartuzumab. However, problems are also emerged with regard to resistance and refractoriness. This chapter also focuses on the current obstacles concerning resistance and refractoriness, as well as provides discussions concerning future directions with regard to molecular categorization to predict response and toxicities leading to select patients most likely to benefit.

show abstract

“…. Im Vergleich mit der alleinigen Chemotherapie verbesserte die Kombination von Trastuzumab und Chemotherapie auch die Lebensqualität[230].…”

unclassified

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

et al. 2019

View full text Add to dashboard Cite

Quality of Life in the Trastuzumab for Gastric Cancer Trial

Cited by 47 publications

References 24 publications

Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer

Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer

Molecular Targeting Therapy for Gastric Cancer: Current Advances and Obstacles

S3-Leitlinie – Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

Contact Info

Product

Resources

About